Kythera Biopharmaceuticals Inc. (KYTH, Financial)(3.4%) (KYTH – $74.98 – NASDAQ), based in Westlake Village, California, is a global biopharmaceutical company that focuses on developing and commercializing medical aesthetics products. On June 17, 2015, Allergan announced that it would acquire Kythera in a merger worth $1.9 billion or $75 per share. Initially, the transaction was to be comprised of cash and stock, but on August 5, Allergan amended the terms of the offering to all cash. The transaction closed on October 1, 2015, after receiving regulatory and shareholder approvals.
From Mario Gabelli (Trades, Portfolio)'s third quarter 2015 ABC Fund commentary.
